Safety of Thai Traditional Medicine Recipes and Herbal Drink in Healthy Volunteers

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211227002

Enrollment

Registered

2021-12-27

Start date

2022-01-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

There have been no scientific studies confirming toxicity. Therefore, to ensure that the dosage of Thai Traditional Medicine Recipes and Herbal Drink is safe and can be used for further research in Phase 2 in patients with COVID-19. COVID-19, Ha-rak, Ha-rak (Kun-So-Pit), Juntaleela, Fataliajorn-Prasa, Herbal drink

Interventions

Healthy volunteers: 6 people will receive Ha-rak (Kun-So-Pit) 3,000 mg PO QID on day 1 to day 10., Healthy volunteers: 6 people will receive Ha-rak 3,000 mg and Juntaleela 3,000 mg PO QID on day 1

Experimental Drug,Experimental Drug,Experimental Drug,Experimental Dietary Supplement,Placebo Comparator Other

Group_1,Group_2,Group_3,Group_4,Placebo

Eligibility

Sex/Gender

All

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Healthy volunteers Male and female, age 20-40 years, 2.No underlying disease, 3.Be literate and able to give consent to participate in the research project by yourself, 4. No smoking, 5. No history of drug and food allergy, 6. No abnormalities were found from physical examination and no clinically significant abnormalities were found from laboratory tests such as Liver function test (AST, ALT, total bilirubin), BUN, creatinine, Complete blood count, Fasting plasma glucose and urine analysis

Exclusion criteria

Exclusion criteria: 1.Have a history of ailments related to renal and hepatic impairment, 2. have a history of drug or drug use, 3. Female volunteers who are pregnant or breastfeeding, 4. Those who are currently participating in other research studies or completed less than 3 months of participating in another research study, 5. Cannot swallow pills or capsules, 6. Have a history of headache or monthly who need frequent pain relievers, 7.Unable to abstain from alcoholic beverages throughout the research period.

Design outcomes

Primary

Measure	Time frame
Adverse reactions and laboratory results Day 0, 6, 11, 16 LFT, Renal function test, CBC, FBS, PT, PTT	—

Secondary

Measure	Time frame
Safe Dosages for Use in Phase 2 Trials Day 0, 6, 11, 16 LFT, Renal function test, CBC, FBS, PT, PTT	—

Countries

Thailand

Contacts

Public ContactSaranyapin Potikanond

Department of Pharmacology Faculty of Medicine, Chiang Mai University

spotikanond@gmail.com0897586228

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026